Frequency Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Frequency Therapeutics generated cash of -$67,283,000, which is less than the previous year. Cash used in financing activities reached the amount of $187,761,000 last year. Net change in cash is therefore $131,642,000.
Cash Flow
| 2017 | -14.61M | -1.86M | 27.97M |
|---|---|---|---|
| 2018 | -17.02M | -436K | 41.71M |
| 2019 | 34.21M | -18.26M | 142.01M |
| 2020 | -45.18M | 10.40M | 56.68M |
| 2021 | -76.05M | -66.12M | 1.35M |
| 2022 | -58.23M | 31.13M | -577K |
| 2023 | -67.28M | 11.16M | 187.76M |
FREQ Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 41.47M | 81.33M | 222.16M | 200.25M | 42.18M | 17.93M | 6.43M |
Operating activities | |||||||
Net income | -81.17M | -81.58M | -84.68M | -26.51M | -18.74M | -19.16M | -20.23M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 3.55M | 2.76M | 2.77M | 1.14M | 813K | 654K | 531K |
Stock-based compensation expense | 0 | 19.83M | 21.75M | 9.98M | 3.60M | 455K | 91K |
| Deferred income tax benefit | 0 | 19.83M | 21.75M | 9.98M | 3.60M | 455K | 91K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 3.1M | -677K | -2.29M | 4.28M | -644K | 869K | -231K |
Cash generated by operating activities | -67.28M | -58.23M | -76.05M | -45.18M | 34.21M | -17.02M | -14.61M |
Investing activities | |||||||
Purchases Of Investments | 0 | -54.22M | -92.44M | -26.34M | -282.61M | 0 | 0 |
Investments In Property Plant And Equipment | -7.83M | 0 | -2.91M | -6.67M | -1.06M | -436K | -1.86M |
Acquisitions Net | 0 | 0 | -29.23M | -43.41M | 282.61M | 0 | 0 |
Cash generated by investing activities | 11.16M | 31.13M | -66.12M | 10.40M | -18.26M | -436K | -1.86M |
Financing activities | |||||||
Common Stock Issued | 45.45M | 60K | 1.29M | 41.68M | 80.06M | 73K | 27K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 187.76M | -577K | 1.35M | 56.68M | 142.01M | 41.71M | 27.97M |
Net Change In Cash | 131.64M | -27.68M | -140.82M | 21.90M | 157.96M | 24.25M | 11.50M |
Cash at end of period | 173.11M | 53.65M | 81.33M | 222.16M | 200.15M | 42.18M | 17.93M |
| Data source | Data source | Data source | Data source | Data source |